Literature DB >> 19008317

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.

Lena Persson1, Cecilia Gälman, Bo Angelin, Mats Rudling.   

Abstract

Hormonal or dietary challenge can stimulate hepatic low-density lipoprotein receptor (LDLR) expression through posttranscriptional mechanisms. We here tested whether such observations may be due to regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9). Treatment with glucagon resulted in a 2-fold increase in hepatic LDLR protein expression, whereas its mRNA levels were reduced; this occurred simultaneously with a 70% reduction in PCSK9 expression. Insulin treatment resulted in responses opposite to those seen by treatment with glucagon. Furthermore, high-dose ethinylestradiol treatment reduced PCSK9 expression by half. Finally, feeding of rats with dietary cholesterol reduced PCSK9 expression, resulting in an increased number of hepatic LDLRs despite a reduction of LDLR mRNA levels. Regulation of PCSK9 occurred in part through sterol regulatory element binding protein-2, but changes in this cholesterol-controlled transcription factor could not explain all hormonal effects seen. We conclude that the hormonal and dietary regulation of hepatic LDLRs also involves posttranscriptional regulation by PCSK9. The identification of PCSK9 regulation by these various treatments is important in understanding of the physiological function of this protein and points to new targets for therapeutic treatments to increase hepatic LDLR numbers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008317     DOI: 10.1210/en.2008-1281

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

2.  Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.

Authors:  Stefano Spolitu; Haruka Okamoto; Wen Dai; John A Zadroga; Erika S Wittchen; Jesper Gromada; Lale Ozcan
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 3.  PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.

Authors:  Petra El Khoury; Sandy Elbitar; Youmna Ghaleb; Yara Abou Khalil; Mathilde Varret; Catherine Boileau; Marianne Abifadel
Journal:  Curr Atheroscler Rep       Date:  2017-10-17       Impact factor: 5.113

4.  Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.

Authors:  Moumita Ghosh; Cecilia Gälman; Mats Rudling; Bo Angelin
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

5.  Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

Authors:  Ji Miao; Praveen V Manthena; Mary E Haas; Alisha V Ling; Dong-Ju Shin; Mark J Graham; Rosanne M Crooke; Jingwen Liu; Sudha B Biddinger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-05-28       Impact factor: 8.311

Review 6.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

7.  Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism.

Authors:  Sara Straniero; Amit Laskar; Christina Savva; Jennifer Härdfeldt; Bo Angelin; Mats Rudling
Journal:  J Lipid Res       Date:  2020-02-21       Impact factor: 5.922

8.  Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.

Authors:  Minhao Wu; Bin Dong; Aiqin Cao; Hai Li; Jingwen Liu
Journal:  Atherosclerosis       Date:  2012-08-24       Impact factor: 5.162

9.  FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.

Authors:  Rongya Tao; Xiwen Xiong; Ronald A DePinho; Chu-Xia Deng; X Charlie Dong
Journal:  J Biol Chem       Date:  2013-08-23       Impact factor: 5.157

10.  Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.

Authors:  Bertrand Cariou; Cédric Langhi; Maëlle Le Bras; Murielle Bortolotti; Kim-Anne Lê; Fanny Theytaz; Cédric Le May; Béatrice Guyomarc'h-Delasalle; Yassine Zaïr; Roland Kreis; Chris Boesch; Michel Krempf; Luc Tappy; Philippe Costet
Journal:  Nutr Metab (Lond)       Date:  2013-01-08       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.